Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies
Doran, Rachel C., Tatsuno, Gwen P., O’Rourke, Sara M., Yu, Bin, Alexander, David L., Mesa, Kathryn A., Berman, Phillip W., Ansari, Aftab A.Volume:
13
Language:
english
Journal:
PLOS ONE
DOI:
10.1371/journal.pone.0196370
Date:
April, 2018
File:
PDF, 13.26 MB
english, 2018